Biotheranostics Announces Inclusion of Breast Cancer Index in the National Comprehensive Cancer Network (NCCN) Breast Cancer Guidelines for Prediction of Benefit from Extended Endocrine Therapy
19. Januar 2021 08:00 ET
|
Biotheranostics, Inc.
San Diego, CA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Breast Cancer Index™ (BCI) has reached an incredible milestone as a new standard of care to predict benefit from extended endocrine therapy for...
Breast Cancer Index® publishes new pivotal data strengthening clinical evidence as a predictive factor of benefit from endocrine therapy
06. September 2019 08:00 ET
|
Biotheranostics, Inc.
San Diego, CA, Sept. 06, 2019 (GLOBE NEWSWIRE) -- SAN DIEGO, Calif., September 5, 2019 – Biotheranostics, Inc. today announced new pivotal data on the Breast Cancer Index® (BCI) published in the...